Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Timing of curative treatment for prostate cancer: a systematic review.

van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG.

Eur Urol. 2013 Aug;64(2):204-15. doi: 10.1016/j.eururo.2013.02.024. Epub 2013 Feb 22. Review.

3.

Active surveillance for prostate cancer: a systematic review of the literature.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS.

Eur Urol. 2012 Dec;62(6):976-83. doi: 10.1016/j.eururo.2012.05.072. Epub 2012 Jun 7. Review.

4.

Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.

van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC.

Eur Urol. 2014 Jun;65(6):1023-31. doi: 10.1016/j.eururo.2014.01.027. Epub 2014 Jan 28. Review.

PMID:
24491309
5.

Contemporary grading for prostate cancer: implications for patient care.

Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI.

Eur Urol. 2013 May;63(5):892-901. doi: 10.1016/j.eururo.2012.10.015. Epub 2012 Oct 17. Review.

PMID:
23092544
6.

Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.

Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL.

Eur Urol. 2015 Jun;67(6):993-1005. doi: 10.1016/j.eururo.2015.01.004. Epub 2015 Jan 21. Review.

PMID:
25616709
7.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
8.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

9.

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy.

Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, Shariat SF, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG.

Eur Urol. 2012 Sep;62(3):382-404. doi: 10.1016/j.eururo.2012.05.047. Epub 2012 Jun 2. Review.

PMID:
22749851
10.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
11.

High-risk prostate cancer: from definition to contemporary management.

Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ.

Eur Urol. 2012 Jun;61(6):1096-106. doi: 10.1016/j.eururo.2012.02.031. Epub 2012 Feb 24. Review.

PMID:
22386839
12.

The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review.

Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, Tewari A, Touijer K, Wilson T, Zorn KC, Eggener SE.

Eur Urol. 2014 May;65(5):918-27. doi: 10.1016/j.eururo.2013.05.026. Epub 2013 May 18. Review.

PMID:
23721959
13.

Positive surgical margins after radical prostatectomy: a systematic review and contemporary update.

Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, Touijer K.

Eur Urol. 2014 Feb;65(2):303-13. doi: 10.1016/j.eururo.2013.07.039. Epub 2013 Aug 3. Review.

PMID:
23932439
14.

Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.

Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, Heidenreich A, Lange S.

Eur Urol. 2011 Nov;60(5):881-93. doi: 10.1016/j.eururo.2011.06.044. Epub 2011 Jun 29. Review.

PMID:
21763066
15.

A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer.

Wolff RF, Ryder S, Bossi A, Briganti A, Crook J, Henry A, Karnes J, Potters L, de Reijke T, Stone N, Burckhardt M, Duffy S, Worthy G, Kleijnen J.

Eur J Cancer. 2015 Nov;51(16):2345-67. doi: 10.1016/j.ejca.2015.07.019. Epub 2015 Aug 5. Review.

16.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
17.

Expectant management for men with early stage prostate cancer.

Filson CP, Marks LS, Litwin MS.

CA Cancer J Clin. 2015 Jul-Aug;65(4):265-82. doi: 10.3322/caac.21278. Epub 2015 May 8. Review.

18.

Active surveillance: oncologic outcome.

Venderbos LD, Bokhorst LP, Bangma CH, Roobol MJ.

Curr Opin Urol. 2013 May;23(3):268-72. doi: 10.1097/MOU.0b013e32835efe8f. Review.

PMID:
23425994
19.

Obesity and prostate cancer: weighing the evidence.

Allott EH, Masko EM, Freedland SJ.

Eur Urol. 2013 May;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013. Epub 2012 Nov 15. Review.

20.

Active surveillance in men with localized prostate cancer: a systematic review.

Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S.

Ann Intern Med. 2012 Apr 17;156(8):582-90. doi: 10.7326/0003-4819-156-8-201204170-00397. Epub 2012 Feb 20. Review.

PMID:
22351515

Supplemental Content

Support Center